Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2004

View Archived Issues

A sustained-release formulation of lanreotide shows efficacy in acromegaly

Good safety and pharmacokinetic profile of intranasal PYY3-36 in healthy volunteers

Oralin reported to improve mealtime glycemic control in type 2 diabetes

Comparison of sleep induction with melatonin, zaleplon, zopiclone and temazepam

Elan submits Prialt NDA amendment

Remoxy results demonstrate Oradur utility

ZymoGenetics licenses to Novo Nordisk rights to IL-28A, IL-29 and IL-31

FDA approval of NeutroSpec for diagnosis of appendicitis

ViraGen licenses Oxford BioMedica's LentiVector gene delivery technology

AltaRex signs distribution agreement with Dompe

sBLA filed for Bexxar

NeoRx files IND for phase II study of STR in metastatic breast cancer

IDEA receives milestone for progression of targeted pain therapeutic

Second clinical trial evaluates trans-NV-04

Pharming and Esteve reach agreement on rhC1INH

NexMed and Schering AG sign Alprox-TD agreement

U.S. phase II study of FM-VP4 planned for next year

Pharmion launches Vidaza

Forest and PAION enter agreement for desmoteplase in U.S. and Canada

Guidant and Miravant to collaborate on cardiovascular PDT development

Dosing commences in phase III trial of TransMID for glioblastoma multiforme

Positive opinion handed down in Europe for Protelos

Wilzin recommended for approval in Europe for Wilson's disease

Novel DPP-IV inhibitors claimed by Boehringer Ingelheim

FKBP12 ligands for neurodegenerative diseases in early development at Taisho

Boehringer Ingelheim patent describes series of cytokine inhibitors

Modulators of tyrosine kinase-mediated signal transduction disclosed in patent

PDE4 inhibitors prepared and tested at elbion

Gastric and intestinal protectants claimed in Altana patent

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026